Chief development officer


Colin Kerr
Published: Thursday, December 3, 2020
Oculis has appointed David Jacobs MD as Chief Development Officer.
A company spokesperson said Dr Jacobs will be based in Oculis’ newly-established US office. In his new role, he will be responsible for leading all development plans and achieving market authorisations by coordinating all regulatory activities required for future New Drug Application submissions to the US Food and Drug Administration (FDA), and the equivalent for regulators in other territories.
www.oculis.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.